Insights

Here’s why the Emyria (ASX:EMD) share price is up 17% to a record high

What did Emyria announce?
The post Here’s why the Emyria (ASX:EMD) share price is up 17% to a record high appeared first on The Motley Fool Australia. –

The Emyria Ltd (ASX: EMD) share price jumped to an all-time high today. This comes after the drug development and care delivery company announced a successful share placement by one of Australia’s largest private investment groups.

During afternoon trade, Emyria shares accelerated to a record high of 39 cents apiece. However, some profit-taking has led its shares slightly lower to 38 cents, up 16.92% at the time of writing.

Emyria secures strategic investment

Investors appear excited about the company bringing its newest investor on board, sending the Emyria share price to uncharted territory.

According to its release, Emyria advised it has received a $5 million strategic investment from Tattarang through a share placement.

Owned by the Forrest family, namely Andrew ‘Twiggy’ Forrest, Tattarang holds an extensive investment portfolio. This includes sectors across agri-food, energy, resources, property, lifestyle and healthtech.

Tattarang and its related entities hold a 36% stake in Fortescue Metals Group Limited (ASX: FMG).

Under the placement, Emyria will issue 20 million shares to Tattarang at a price of 25 cents each. Once completed, this will give Tattarang a 7.3% interest in Emyria.

In addition to the placement, 10 million options will be issued at an exercise price of 40 cents per option. The expiry date is two years from the expected date of 24 November 2021.

The funds received will be allocated to Emyria’s synthetic cannabinoid registration programs with the Therapeutic Goods Administration (TGA), and the United States Food and Drug Administration (FDA).

Furthermore, the company is also seeking to advance its novel MDMA-analogue development program with the University of Western Australia.

Emyria managing director, Dr Michael Winlo commented:

We are delighted to receive Tattarang’s strong support with this placement.

Emyria is the only ASX-listed company that controls patient-treating clinics and a clinical-trial-grade data system and uses these assets to accelerate the development and registration of new drugs, digital technologies and care models.

Our current leading programs cover synthetic cannabinoid-based pharmaceuticals, MDMA-assisted therapy and novel psychedelic drug development. We are very pleased to welcome Tattarang to be part of this next phase of growth.

Emyria share price summary

Over the past 12 months, Emyria shares have registered gains of more than 400%, with year-to-date hovering above 300% in 2021.

Emyria presides a market capitalisation of roughly $58.52 million and has approximately 153.99 million shares on its registry.

The post Here’s why the Emyria (ASX:EMD) share price is up 17% to a record high appeared first on The Motley Fool Australia.

Should you invest $1,000 in Emyria right now?

Before you consider Emyria, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Emyria wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why is the Flight Centre (ASX:FLT) share price tumbling 6% to a 2-month low?

BrainChip (ASX: BRN) share price rockets 16% on Megachips deal

Why is the Santos (ASX:STO) share price falling on Monday?

Vulcan Energy (ASX:VUL) share price leaps 10% on new lithium deal

Preparing for inflation? This fund manager believes these shares offer protection

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!